- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01565798
Efficacy Of Copper To Reduce Acquisition Of Microbes and Healthcare-acquired Infections
Copper Antimicrobial Research Program: Environmental and Patient Sampling For Indicator Organisms To Determine The Efficacy Of Copper To Reduce Acquisition Of Microbes From The Patient Care Environment
CONTEXT: Healthcare-acquired infections (HAI) cause substantial patient morbidity and mortality. Commonly touched items in the patient care environment harbor microorganisms that may contribute to HAI risk. Thus, reduction in the surface bioburden may be an effective strategy to reduce HAI. Inherent biocidal capabilities of copper surfaces offer a theoretical advantage to conventional cleaning, as disinfection is continuous rather than episodic.
OBJECTIVE: Determine whether placement of copper-alloy surfaced objects in an intensive care unit (ICU) reduce risk of HAI.
DESIGN: An intention to treat study where patients are sequentially placed into rooms with or without copper-alloy surfaced objects.
SETTING: The ICUs of three hospitals, a tertiary academic hospital, an academic cancer center, and a Veteran's Administration Medical Center.
PATIENTS: Any patient 18 years of age or older who required admission to an ICU at a study hospital is eligible for placement into a study room if available.
INTERVENTION: Placement of copper-alloy surfaced objects in an ICU room. MAIN OUTCOME MEASURE: Rate of incident HAI and/or colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) in each type of room.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
patients 18 years and older requiring admission to an ICU at one of the study sites were eligible
Exclusion Criteria:
- less than 18 years of age or
- pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Copper Surfaced Room
Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
|
Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
|
|
No Intervention: Standard Surfaced Room
Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of incident HAI and/or colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) in each type of room.
Time Frame: July 2010 to June 2011 (up to 1 year)
|
Patients prospectively followed from ICU admission to hospital discharge for acquisition of HAI and/or colonization with MRSA or VRE
|
July 2010 to June 2011 (up to 1 year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microbial burden and risk of HAI
Time Frame: July 2010 to June 2011 (up to 1 year)
|
The risk of HAI among patients admitted to ICU will be assessed by microbial burden of environment.
|
July 2010 to June 2011 (up to 1 year)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael G Schmidt, PhD, Medical University of South Carolina
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DOD W81XWH-07-C-0053
- Effect of Copper on HAI (Other Grant/Funding Number: U.S. Army Material Command Contract W81XWH-07-C-0053)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthcare-acquired Infection
-
Eastern Virginia Medical SchoolCupron Inc.CompletedHospital Acquired InfectionUnited States
-
University of ZurichTerminatedHospital-acquired Pneumonia | Healthcare Associated Infection | Infection PreventionSwitzerland
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical MedicineCompletedCommunity Acquired Pneumonia | Lower Respiratory Tract Infection | Hospital Acquired PneumoniaUnited Kingdom
-
Ruta NutautieneEnrolling by invitationHospital Acquired Pneumonia | Community Acquired Pneumonia (CAP)Lithuania
-
Fundació Institut de Recerca de l'Hospital de la...CompletedCommunity-acquired Pneumonia | Healthcare-associated PneumoniaSpain
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)CompletedHealthcare-Associated InfectionsUnited States
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedEnterobacteriaceae Infections | Community-Acquired Infections | Healthcare Associated Infection | Carbapenem-Resistant Enterobacteriaceae InfectionUnited States
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
PfizerTerminatedHospital Acquired Pneumonia | Complicated Intra Abdominal Infections | Ventilator Acquired PneumoniaChina
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
Clinical Trials on Copper-alloy surfaced patient care objects
-
CodelcoCompletedNosocomial InfectionsChile
-
University Hospital, MontpellierCompleted